Silver Book Fact

For beneficiaries with wet age-related macular degeneration (AMD), annual Medicare part B payments for vision care increased from $1,504 per beneficiary in 1994 to $3,263 in 2006–due in large part to anti-VEGF treatments.

Day, Shelley, Kofi Acquah, Paul P. Lee, Prithvi Mruthyunjaya, and Frank A. Sloan. Medicare Costs for Neovascular Age-Related Macular Degeneration, 1994-2007. Ophthalmol. May 2011; 152(6): 1014-20. http://www.ajo.com/article/S0002-9394%2811%2900410-7/abstract

Reference

Title
Medicare Costs for Neovascular Age-Related Macular Degeneration, 1994-2007
Publication
Ophthalmol
Publication Date
May 2011
Authors
Day, Shelley, Kofi Acquah, Paul P. Lee, Prithvi Mruthyunjaya, and Frank A. Sloan
Volume & Issue
Volume 152, Issue 6
Pages
1014-20
URL
Read Full Resource

Categories

  • Cost of Disease
  • Economic Burden

Related Facts

  • By 2020, the number of Americans age 40 and older with low vision is projected to reach 3.9 million– growing from 2.4 million in 2004.  
  • Annual Direct and Indirect Costs of Diabetic Retinopathy
     
  • More than 1 in 10 Americans over the age of 80 has advanced age-related macular degeneration (AMD)– 1.08 million Americans 80 and older.  
  • Glaucoma affects less than 1 in 100 people ages 40 to 49.  That rate increases to close to 1 in 10 for individuals over the age of 80.  
  • The number of people in the U.S. with visual impairment or blindness is expected to double to more than 8 million by 2050.